abs322.txt	burkitt	lymphoma	(bl)	is	the	most	common	pediatric	cancer	in	sub-saharan	africa(ssa)		and	also	occurs	frequently	among	adolescents	and	young	adults	(ayas)	often	associated	with	hiv		treating	bl	in	ssa	poses	particular	challenges	although	highly	effective		high-intensity	cytotoxic	treatments	used	inresource-rich	settings	are	usually	not	feasible		and	lower-intensity	continuousinfusion	approaches	are	impractical		in	this	article		based	on	evidence	from	theregion		we	review	management	strategies	for	ssa	focused	on	diagnosis	and	use	ofprephase	and	definitive	treatment		additionally		potentially	better	approachesfor	risk	stratification	and	individualized	therapy	are	elaborated		compared	withhistorical	very	low-intensity	approaches		the	relative	safety		feasibility		andoutcomes	of	regimens	incorporating	anthracyclines	and/or	high-dose	systemicmethotrexate	for	this	population	are	discussed		along	with	requirements	toadminister	such	regimens	safely		finally		research	priorities	for	bl	in	ssa	areoutlined	including	novel	therapies		to	reduce	the	unacceptable	gap	in	outcomesfor	patients	in	ssa	vs	high-income	countries	(hics)		sustained	commitment	toincremental	advances	and	innovation		as	in	cooperative	pediatric	oncology	groupsin	hics		is	required	to	transform	care	and	outcomes	for	bl	in	ssa	throughinternational	collaboration	
